Amgen hit by T-VEC's Phase III survival miss
This article was originally published in Scrip
Executive Summary
Amgen's talimogene laherparepvec (T-VEC) missed the secondary endpoint of overall survival in a Phase III melanoma clinical trial despite the oncolytic immunotherapy's previously reported success in the primary endpoint of durable response rate.